Amgen cholesterol drug could get EU green light this week

May 19, 2015 4:20 PM

18 0

Amgen cholesterol drug could get EU green light this week

LONDON Amgen's new cholesterol drug Repatha could be recommended for approval in Europe as early as this week, putting it ahead in a race with a rival product from Sanofi.

Repatha, or evolocumab, belongs to a new class of cholesterol-lowering drugs known as PCSK9 inhibitors that clinical trials suggest may slash the risks of heart attacks compared to standard treatment alone.

Read more

To category page

Loading...